(CNN) — Weekly injections of semaglutide medications like Ozempic significantly reduce the risk of serious kidney outcomes, major cardiovascular events and death among people who have type 2 diabetes and
Hosts break down the FLOW trial, take a deep dive into secondary findings, and provide insight into how this alters the perception of the role for semaglutide in management of CKD in type 2 diabetes.